Johnson & Johnson has now put four software releases onto the same lung biopsy robot in eighteen months. MedTech Dive reported the latest clearance, Monarch Quest 3, on Monday. Most of the coverage leads with the AI, because the update draws nodule boundaries automatically during planning. The AI is the least interesting part of it.
What actually shipped
Monarch is the robotic bronchoscopy system J&J uses to reach nodules deep in the lung for biopsy. Per MedTech Dive, Quest 3 adds AI-generated nodule boundaries during pre-procedure planning, updated navigation and visual guidance during the case, and a 3D view that helps the operator hold the relationship between the controls and the patient's anatomy. The cart in the room did not change. This is the fourth major software launch on that platform in eighteen months.
Monarch competes with Intuitive's Ion and Noah Medical's Galaxy in robotic bronchoscopy. J&J also won FDA authorization for its Ottava soft tissue robot in July, which puts the company up against da Vinci and Medtronic's Hugo on a second front. Four cleared software releases in eighteen months works out to a release roughly every four and a half months, through a federal review, on a device already sitting in hospitals. That cadence is harder to build than the algorithm riding on it.
The cadence is an architecture decision
Whether you can ship a software-only improvement to a cleared device gets settled years before you file anything. It depends on how tightly your software is bound to your hardware, how your requirements and risk files are organized, and whether your verification strategy lets you re-test a changed function without re-testing the machine around it. Get those wrong and every improvement drags the whole device back into review. Get them right and you can hand the FDA a small, well-bounded change and keep your customers on the current version.
I led the de novo effort at Galen Robotics, and the lesson that stuck was how much of a submission comes down to the boundary you drew around the device rather than the device itself. Founders tend to treat that boundary as paperwork to be sorted out once the engineering is done. It is engineering. Draw it in the wrong place and you have signed up to re-open your whole file every time somebody improves the navigation.
That makes it a product decision, and it belongs to whoever owns the product. The roadmap question runs past what the next feature does, to whether you can put that feature in the hands of the customers who already bought the machine.
The AI claim is narrow on purpose
Look at how the AI is actually described. It generates nodule boundaries during planning. That is a specific job, on a specific input, producing an output somebody outside the company could examine. Nobody at J&J announced that the robot now understands the lung.
That gap is the difference between a claim written for a reviewer and a claim written for a news cycle. My test on any AI announcement is whether the claim can be checked by someone with no financial stake in it, inside the window where checking still changes anything. A lot of what the big labs put out fails that test by design, and the pressure from it lands on hardware founders as a board question about what you are doing with AI. A regulated product forces the better answer, because you have to write the claim in a form a stranger can evaluate. If you cannot state your AI feature that way, what you have is positioning.
Founders in diagnostics, industrial robotics, and defense autonomy are all being pushed toward the same announcement. The ones with a regulator or a qualification authority in the loop get handed the discipline for free. Everybody else has to impose it.
What I would protect on that roadmap is the release clock, ahead of any single algorithm riding on it. Intuitive did not win the operating room with a better arm. It won by solving so much of the surrounding problem that leaving stopped making sense to anyone, and a company that can improve a cleared product every few months is building that same hold one release at a time. The box gets copied. The clock is harder.
From Dave’s video library
Dave walks through how P.T. Barnum drew 38 million people, and why the same moves keep showing up in AI announcements.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour working session →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →